18F-fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1a expression in oral squamous cell carcinoma

Journal of Nuclear Medicine

Volumn 54, Issue 7, 2013, Pages 1060-1065

  Sato, Jun ^a   Kitagawa, Yoshimasa ^a   Yamazaki, Yutaka ^a   Hata, Hironobu ^a   Okamoto, Shozo ^b   Shiga, Tohru ^b   Shindoh, Masanobu ^a   Kuge, Yuji ^a   Tamaki, Nagara ^b  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

FMISO PET; HIF 1 ; Hypoxia; Oral squamous cell carcinoma

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; FLUORODEOXYGLUCOSE F 18; HYPOXIA INDUCIBLE FACTOR 1ALPHA; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; DIAGNOSTIC AGENT; DRUG DERIVATIVE; MISONIDAZOLE; OXYGEN; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CANCER STAGING; CELL HYPOXIA; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOUTH SQUAMOUS CELL CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RADIOLOGICAL PARAMETERS; STANDARDIZED UPTAKE VALUE; FMISO PET; HIF-1Α; HYPOXIA; METABOLISM; METHODOLOGY; MIDDLE AGED; MOUTH TUMOR; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; STATISTICS;

FMISO PET; HIF-1Α; HYPOXIA; ORAL SQUAMOUS CELL CARCINOMA;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; FEMALE; HUMANS; MALE; MIDDLE AGED; MISONIDAZOLE; MOUTH NEOPLASMS; OXYGEN; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STATISTICS AS TOPIC;

EID: 84879912006     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.114355     Document Type: Article

References (36)

1. Wang W, Lee NY, Georgi JC, et al. Pharmacokinetic analysis of hypoxia 18Ffluoromisonidazole dynamic PET in head and neck cancer. J Nucl Med. 2010;51:37-45.
2. Janssen HL, Haustermans KM, Balm AJ, et al. Hypoxia in head and neck cancer: how much, how important? Head Neck. 2005;27:622-638.
3. Eschmann SM, Paulsen F, Bedeshem C, et al. Hypoxia-imaging with 18F-misonidazole and PET: changes of kinetics during radiotherapy of head-and-neck cancer. Radiother Oncol. 2007;83:406-410.
4. Koh WJ, Rasey JS, Evans ML, et al. Imaging of tumor hypoxia in human tumors with [F-18] fluoromisonidazole. Int J Radiat Oncol Biol Phys. 1992;22:199-212.
5. Rasey JS, Koh WJ, Fvans ML, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [F-18] fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys. 1996;36:417-428.
6. Rajendran JG, Wilson DC, Conrad EU, et al. [18F]FMISO and [18F] FDG PET imaging in soft tissue sarcoma: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging. 2003;30:695-704.
7. Jansen JFA, Schöder H, Lee NY, et al. Noninvasive assessment of tumor microenviroment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases. Int J Radiat Oncol Biol Phys. 2010;77:1403-1410.
8. Lee ST, Scott AM. Hypoxia positron emission tomography imaging with 18- fluoromisonidazole. Semin Nucl Med. 2007;37:451-461.
9. Okamoto S, Shiga T, Yasuda K, et al. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer. J Nucl Med. 2013;54:201-207.
10. Harada H, Inoue M, Itasaka S, et al. Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels. Nat Commun. 2012;3:783.
11. Nordsmark M, Bentzen S, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy: an international multi-center study. Radiother Oncol. 2005;77:18-24.
12. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3:721-732.
13. Lin PY, Yu CH, Wang JT, et al. Expression of hypoxia-inducible factor-1a is significantly associated with the progression and prognosis of oral squamous cell carcinomas in Taiwan. J Oral Pathol Med. 2008;37:18-25.
14. Semenza GL. Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol. 2009;19:12-16.
15. Chan DA, Giaccia AJ. Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev. 2007;26:333-339.
16. Liao D, Johnson RS. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev. 2007;26:281-290.
17. Kizaka-Kondoh S, Tanaka S, Hiraoka M. Imaging and targeting of the hypoxiainducible factor 1-active microenvironment. J Toxicol Pathol. 2009;22:93-100.
18. Liang X, Zheng M, Jiang J, et al. Hypoxia-inducible factor-1 alpha, in association with TWIST2 and SNIP1, is a critical prognostic factor in patients with tongue squamous cell carcinoma. Oral Oncol. 2011;47:92-97.
19. Uehara M, Sano K, Ikeda H, et al. Hypoxia-inducible factor 1 alpha in oral squamous cell carcinoma and its relation to prognosis. Oral Oncol. 2009;45:241-246.
20. Roh JL, Cho KJ, Kwon GY, et al. The prognostic value of hypoxia markers in T2-staged oral tongue cancer. Oral Oncol. 2009;45:63-68.
21. Fillies T, Werkmeister R, van Diest P, et al. HIF1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinoma of the oral floor. BMC Cancer. 2005;5:84-91.
22. Liu SY, Chang LC, Pan LF, et al. Clinicopathologic significance of tumor celllined vessel and microenviroment in oral squamous cell carcinoma. Oral Oncol. 2008;44:277-285.
23. Aebersold DM, Burri P, Beer KT, et al. Expression of hypoxia-inducible factor 1 alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 2001;61:2911-2916.
24. Barnes L, Eveson J, Reichart P, et al. World Health Organization Classification of Tumors, Pathology and Genetics of Tumors of the Head and Neck. International Agency for Research on Cancer. Lyon, France: IARC Press; 2005.
25. Sobin LH, Wittenkind CH. TNM Classification of Malignant Tumors. 5th ed. New York, NY: John Wiley & Sons, Inc.; 1997.
26. Yamamoto E, Kohama G, Sunakawa H, et al. Mode of invasion, bleomycin sensitivity, and clinical course in squamous cell carcinoma of the oral cavity. Cancer. 1983;51:2175-2180.
27. Schliephake H. Prognostic relevance of molecular markers of oral cancer: a review. Int J Oral Maxillofac Surg. 2003;32:233-245.
28. Németh Z, Velich N, Bogdan S, et al. The prognostic role of clinical, morphological and molecular markers in oral squamous cell tumors. Neoplasma. 2005;52:95-102.
29. Kudo T, Ueda M, Kuge Y, et al. Imaging of HIF-1-active tumor hypoxia using a protein effectively delivered to and specifically stabilized in HIF-1-active tumor cells. J Nucl Med. 2009;50:942-949.
30. Kudo T, Ueda M, Konishi H. PET imaging of hypoxia-inducible factor-1 active tumor cells with pretargeted oxygen-dependent degradable streptavidin and a novel 18F-Labeled biotin derivative. Mol Imaging Biol. 2011;13:1003-1010.
31. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med. 2008;49(suppl 2):129S-148S.
32. Serganova I, Doubrovin M, Vider J, et al. Molecular imaging of temporal dynamics and spatial heterogeneity of hypoxia-inducible factor-1 signal transduction activity in tumour in living mice. Cancer Res. 2004;64:6101-6108.
33. Bos R, Van Der Groep P, Greijer AE, et al. Levels of hypoxia-inducible factor-1 alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer. 2003;97:1573-1581.
34. Beasley NJP, Leek R, Alam M, et al. Hypoxial-inducible factors HIF-1a and HIF-2a in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res. 2002;62:2493-2497.
35. Jiang BH, Semenza GL, Bauer C, et al. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol. 1996;271:C1172-C1180.
36. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumor. Nat Rev Cancer. 2008;8:705-713.